Skip to main content
. 2014 Mar 24;105(5):528–536. doi: 10.1111/cas.12387

Figure 3.

Figure 3

Diffuse-type gastric carcinoma (DGC) cell lines have different sensitivities to Met, fibroblast growth factor receptor (FGFR) and Src inhibitors. (a) Viability of DGC cell lines cultured in the presence of Met inhibitor PF-2341066 (300 nM), FGFR inhibitor PD-173074 (300 nM), or Src inhibitor saracatinib (3 μM) for 4 days. Numbers shown are mean values of relative cell viability (n = 4). The sensitivity of each cell line to each inhibitor is indicated by the increasing intensity of the red signal on a blue background. (b) Immunoblot analysis for expression and phosphorylation of Src, FGFR and FRS2.